DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Objections
Claim 3 is objected to because of the following informalities: “sight” should be “site”.
Claim 8 is objected to because of the following informalities: hydrochloric acid appears as either “HC l” or “HC 1”.
Appropriate corrections are required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 10 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claim 10, the phrase "sheet-like" renders the claim(s) indefinite because the claim(s) include(s) elements not actually disclosed (those encompassed by "sheet-like"), thereby rendering the scope of the claim(s) unascertainable. See MPEP § 2173.05(d). The specification states, “sheet, i.e., a planar shape” (para.[0033]). However the extent of “-like” is not discussed or elaborated.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1-10 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by Malaviya (US 20040166169) as evidenced by Freytes (Freytes, D.O., et al., Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix, Biomaterials 29 (2008) 1630-37).
Malaviya teaches “a porous extracellular matrix scaffold for repairing or regenerating body tissue” (para.0002; see title; abstract; paras.0009-16, 0019-78; claims 1-99). The scaffold comprises a “cleaned, processed, sterilized” (para.0006) extracellular matrix material such as the small intestine submucosa (SIS) in the form of a “porous reticulated body” with pores having nominal pore size up to 700 microns, e.g., 100-150 µm and 300 µm (claims 52-58; Examples 2, 3 paras.0047-61). Malaviya does not expressly refer to devitalized or decellularized ECM material. First, however it teaches using “cleaned, processed, sterilized” (para.0006) extracellular matrix material. Second, Malaviya expressly distinguishes “purified” ECM material as having glycoproteins and other native material substantially removed (para.0078; claims 67, 73). Third, Freytes evidences that “biologic scaffolds are typically prepared by decellularization of intact tissues or organs” (p.1630 left col.).
The implantable device further comprises a biocompatible inorganic material (claim 54), which includes the minerals in instant claims 2 and 12 (para.0072).
Regarding claim 3, the “scaffold comprises a porous body of naturally occurring extracellular matrix pieces that are interconnected to define an interior surface of the body” (para.0012 (emphasis added)).
Regarding claim 10, Malaviya teaches scaffolds made from lyophilized suspension of ECM material on a culture plate, which would yield a flat product.
Regarding claims 4-6, 8, and 9, Malaviya does not teach all of the recited process steps for preparing the medical device of claim 1. However it is noted that the “patentability of a product does not depend on its method of production” and “[i]f the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” MPEP §2113 (citations omitted). Here Malaviya teaches a product as recited in claim 1. Therefore the process steps in claims 4-6, 8, and 9 do not render the claims patentable even though Malaviya’s product was made by a different process.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over Malaviya (20040166169) as evidenced by and in view of Freytes (Freytes, D.O., et al., Preparation and rheological characterization of a gel form of the porcine urinary bladder matrix, Biomaterials 29 (2008) 1630-37).
Regarding claims 11 and 12, Malaviya does not expressly teach a gel product comprising a milled scaffold material and an aqueous solution.
Freytes is drawn to biologic scaffolds and teaches gel form of porcine urinary bladder matrix or UBM (title; abstract; p.1634-36). Specifically UBM is decellularized, lyophilized, comminuted, solubilized with pepsin, and mixed with collagen type I, 0.1 N NaOH, and phosphate buffered saline, resulting in formation of a gel (p.1631 2.1, 2.2, 2.4). The gel supported growth of rat aortic smooth muscle cells when in vitro (p.1633 3.2).
It would have been prima facie obvious for one having ordinary skill in the art before the effective filing date to combine the teachings of Malaviya and Freytes and form Malaviya’s scaffold into a gel as Freytes teaches and as recited in the instant claim(s). The skilled person would have been motivated to do so because both are drawn to tissue scaffold comprising ECM material, and Freytes teaches that “ECM gels with appropriate viscosities could be delivered via minimally invasive surgical techniques with the ability to conform to three-dimensional spaces after injection” (p.1631 left col.).
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-12 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 9119831.
Although the claims at issue are not identical, they are not patentably distinct from each other because both claim sets are drawn to a medical device comprising: a devitalized, solidified, porous extracellular matrix foam material derived from a mammal comprising a plurality of pores having a diameter in the range of about 1 micron to 500 microns. The difference is that the ‘831 patent claims recite a bioactive wound healing material which is a medical device, and further requires a basic solution which is narrowing and therefore anticipates the present claims. The ‘831 patent claims recite broader ranges of powdered ECM, however they also recite “a particle size in the range of about 100 microns to about 400 microns” (claim 15) which is narrower than the range in claims 1 and 11 here.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to H. S. PARK whose telephone number is (571)270-5258. The examiner can normally be reached on weekdays.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at (571)272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/H. SARAH PARK/Primary Examiner, Art Unit 1614